Biocon Chief Kiran Mazumdar Shaw leads investment in women's health platform Gytree
Gytree will be directly available to consumers through the easy to use web-app, but also to corporations who prioritise female workforce and their health.
New Delhi: Gytree.com announced its first round of fundraising, led by Biocon's Kiran Mazumdar Shaw, Rainmatter Investments, Ajay Srinivasan former CEO of Aditya Birla Capital, Anubhuti Sharma of San Francisco-based Millie Clinic amongst others.Founded by Shaili Chopra, Gytree.com uses technology to provide women with an intelligent dashboard, experts and personalised journeys for better...
New Delhi: Gytree.com announced its first round of fundraising, led by Biocon's Kiran Mazumdar Shaw, Rainmatter Investments, Ajay Srinivasan former CEO of Aditya Birla Capital, Anubhuti Sharma of San Francisco-based Millie Clinic amongst others.
Founded by Shaili Chopra, Gytree.com uses technology to provide women with an intelligent dashboard, experts and personalised journeys for better health outcomes.
“We need to build female first products in health and for way too long India has ignored that,” says Kiran Mazumdar Shaw, Chairperson of Biocon, India’s largest biopharmaceutical company. “Gytree.com fills an important gap in using technology to solve for personalised health needs of women through products and services. I am delighted to lend support to Shaili and her team on this purposeful journey.”
“What Indian women need is a 360-degree approach to care, due to inter-related symptoms and outcomes. India’s current health systems do not provide that. Gytree.com offers a patient-centric team to bridge this gap across all life stages, from menstruation to menopause,” says Shaili Chopra.
Almost 60% of working women in India quit the workforce due to health related issues. According to the National Health Portal of India, more than 32 million women in India suffer from incurable conditions ranging from PCOS to endometriosis, and infertility, and they lack the necessary handholding to manage this effectively.
"Gytree.com would be the first platform of its kind to provide assistance at every step: symptom identification, timely diagnosis and long-term management," the release stated.
The Rainmatter Investments team said of their investment in Gytree, “Helping people make healthy choices has been a priority for us at Rainmatter. Of all the health issues in India, the lack of focus on women's healthcare has to be the biggest. This is why we're excited to join Shaili and the team as they tackle this pressing issue by building a comprehensive and exclusive healthcare ecosystem for women.”
Investor in Gytree and former CEO of Aditya Birla Capital, Ajay Srinivasan said, "I am excited by femtech as a sector and believe solutions targeted at getting women to lead better lives will scale up and drive growth. Usage of tech can help make solutions more affordable and universal, something India's 600 mn plus women need immediately."
Gytree will be directly available to consumers through the easy to use web-app, but also to corporations who prioritise female workforce and their health.
The virtual platform gives consumers services wrapped around the core offering of gynaecology that includes mental health support, nutrition counselling, and regular digital health checks linked to their primary needs. Patients get access to at-home lab tests curated for women and round the clock patient care and virtual check-in options. “At Gytree we have several benefits for women seeking such support. They not only get access from anywhere, anytime, but are also able to discuss personal and intimate health details in a safe and discreet environment,” adds Chopra.
Read also: Biocon Biologics recognized as Company with Great Managers at Great Manager Awards 2022
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd